Compare WSE & DVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSE | DVA |
|---|---|---|
| Founded | 2010 | 1994 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Misc Health and Biotechnology Services |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6B | 14.9B |
| IPO Year | 2025 | 2003 |
| Metric | WSE | DVA |
|---|---|---|
| Price | $10.69 | $156.57 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 14 | 8 |
| Target Price | $17.01 | ★ $222.29 |
| AVG Volume (30 Days) | ★ 2.4M | 721.1K |
| Earning Date | 12-01-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 10.27 |
| Revenue | N/A | ★ $13,643,069,000.00 |
| Revenue This Year | $20.63 | $4.44 |
| Revenue Next Year | $16.35 | $3.53 |
| P/E Ratio | ★ N/A | $16.62 |
| Revenue Growth | N/A | ★ 6.46 |
| 52 Week Low | $10.56 | $101.00 |
| 52 Week High | $13.66 | $247.49 |
| Indicator | WSE | DVA |
|---|---|---|
| Relative Strength Index (RSI) | 42.60 | 29.77 |
| Support Level | N/A | $145.58 |
| Resistance Level | $13.37 | $156.54 |
| Average True Range (ATR) | 0.35 | 6.42 |
| MACD | 0.01 | -3.14 |
| Stochastic Oscillator | 13.21 | 8.47 |
Wise is a currency conversion platform that matches, where possible, offsetting currency transactions across borders to reduce costs. The group focuses primarily on private clients and small and midsize enterprises, but it is building out its platform business aimed at providing its services as a backend solution to banks. By operating local accounts in each jurisdiction Wise sends money to or receives money from, this fintech offers faster and cheaper currency transfer services than incumbents (banks). Wise has started to broaden its product offering, issuing its clients debit cards and allowing customers to invest funds in various asset management products.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.